Breaking News Bar

Business News and Information

Regional One Health and UTHSC to conduct clinical trials of Regeneron's COVID treatment

The Regeneron drug candidate consists of a two-antibody cocktail that binds to SARS-CoV2’s spike protein, which potentially neutralizes the virus’ ability to attach to human cells.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear